Key result
Liposomal encapsulated anti-cancer agents represent an advanced and versatile drug delivery technology with several approved formulations for metastatic breast cancer and Kaposi's sarcoma.
Liposomal encapsulated anti-cancer agents represent a versatile drug delivery technology with several approved formulations for specific cancers.
Answers are grounded in this paper and cite their sources.
Supports approved liposomal use in metastatic breast cancer and Kaposi's sarcoma; leaves open comparative trials for expanded indications.
Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anti-cancer agents.
No takes yet. Share an insight, caveat, or question.
Hofheinz et al. (2005) conducted a review in Cancer. Liposomal encapsulated anti-cancer drugs was evaluated. Liposomal encapsulated anti-cancer agents represent an advanced and versatile drug delivery technology with several approved formulations for metastatic breast cancer and Kaposi's sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: